Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 10 (May 15), 2004: pp. 1878-1885
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.12.002

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bepler, G.
Right arrow Articles by Robinson, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bepler, G.
Right arrow Articles by Robinson, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non–Small-Cell Lung Cancer

Gerold Bepler, Swati Sharma, Alan Cantor, Ashish Gautam, Eric Haura, George Simon, Anupama Sharma, Eric Sommers, Lary Robinson

From the Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Address reprint requests to Gerold Bepler, MD, PhD, Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, MRC-4 West, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: beplerg{at}moffitt.usf.edu

PURPOSE: RRM1 has important functions in the determination of the malignant phenotype. It controls cell proliferation through deoxynucleotide production and metastatic propensity through PTEN induction. It is located in a region of loss of heterozygosity in non–small-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC.

PATIENTS AND METHODS: A retrospective data set of 49 patients and a prospective data set of 77 patients with resectable NSCLC were studied. RNA was extracted from tumor and normal lung tissue, and expression of the genes RRM1, PTEN, and RRM2 was determined by real-time quantitative polymerase chain reaction.

RESULTS: RRM1 expression was significantly correlated with PTEN and RRM2 expression in tumor tissue. RRM1 and PTEN expression in tumor tissue was highly predictive of overall (P = .011 and .018, respectively) and disease-free survival (P = .002 and .026, respectively). Patients with high levels of expression lived longer and had disease recurrence later than patients with low levels of RRM1 and PTEN. In a multivariate analysis, high RRM1 expression was predictive of long survival independent of tumor stage, performance status, and weight loss.

CONCLUSION: RRM1 is a biologically and clinically important determinant of malignant behavior in NSCLC. Knowing the level of expression of this gene adds significant information to management decisions independent of the currently used outcome predictors of tumor stage, performance status, and weight loss. Future clinical trials should stratify patients based on expression of this gene to avoid unwanted biases.

Supported in part by grant No. R01-CA102726 from the National Cancer Institute, Bethesda, MD.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al.
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Clin. Cancer Res., December 1, 2008; 14(23): 7917 - 7923.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
N. Engl. J. Med., February 22, 2007; 356(8): 800 - 808.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, and G. Simon
RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 10, 2006; 24(29): 4731 - 4737.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Gautam and G. Bepler
Suppression of Lung Tumor Formation by the Regulatory Subunit of Ribonucleotide Reductase.
Cancer Res., July 1, 2006; 66(13): 6497 - 6502.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Cappuzzo, L. Toschi, G. Tallini, G. L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, et al.
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
Ann. Onc., July 1, 2006; 17(7): 1120 - 1127.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. W. Liu, S. T. Chen, and H. P. Liu
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Eur. Respir. J., December 1, 2005; 26(6): 1002 - 1008.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Han, J. D. Ritzenthaler, B. Wingerd, and J. Roman
Activation of Peroxisome Proliferator-activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Increases the Expression of Prostaglandin E2 Receptor Subtype EP4: THE ROLES OF PHOSPHATIDYLINOSITOL 3-KINASE AND CCAAT/ENHANCER-BINDING PROTEIN {beta}
J. Biol. Chem., September 30, 2005; 280(39): 33240 - 33249.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Wang and M. You
Five Loci, SLT1 to SLT5, Controlling the Susceptibility to Spontaneously Occurring Lung Cancer in Mice
Cancer Res., September 15, 2005; 65(18): 8158 - 8165.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura
Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer
Chest, July 1, 2005; 128(1): 308 - 316.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Ferraro, G. Bepler, S. Sharma, A. Cantor, and E. B. Haura
EGR1 Predicts PTEN and Survival in Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 20, 2005; 23(9): 1921 - 1926.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online